No recent analyst price targets found for LBTSF.
Latest News for LBTSF
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
DENVER--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company's presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin…
Almirall, S.A. (LBTSF) Q4 2025 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q4 2025 Earnings Call Transcript
Almirall, S.A. (LBTSF) Presents at 44th Annual J.P.
Almirall, S.A. (LBTSF) Presents at 44th Annual J.P.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LBTSF.
Senate Trading
No Senate trades found for LBTSF.
U.S. House Trading
No House trades found for LBTSF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.